Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection



Adegbola, Adebanjo, Abutaima, Rana, Olagunju, Adeniyi ORCID: 0000-0002-6588-5749, Ijarotimi, Omotade, Siccardi, Marco ORCID: 0000-0002-3539-7867, Owen, Andrew ORCID: 0000-0002-9819-7651, Soyinka, Julius and Bolaji, Oluseye
(2018) Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62 (10). e01252-e01218.

Access the full-text of this item by clicking on the Open Access link.
[img] Text
Clean Manuscript File_26072018_AO.docx - Submitted version

Download (542kB)

Abstract

Artemether-lumefantrine is often coadministered with efavirenz-based antiretroviral therapy for malaria treatment in HIV-infected women during pregnancy. Previous studies showed changes in lumefantrine pharmacokinetics due to interaction with efavirenz in nonpregnant adults. The influence of pregnancy on this interaction has not been reported. This pharmacokinetic study involved 35 pregnant and 34 nonpregnant HIV-malaria-coinfected women receiving efavirenz-based antiretroviral therapy and was conducted in four health facilities in Nigeria. Participants received a 3-day standard regimen of artemether-lumefantrine for malaria treatment, and intensive pharmacokinetic sampling was conducted from 0.5 to 96 h after the last dose. Plasma efavirenz, lumefantrine, and desbutyl-lumefantrine were quantified using validated assays, and pharmacokinetic parameters were derived using noncompartmental analysis. The median middose plasma concentrations of efavirenz were significantly lower in pregnant women (n = 32) than in nonpregnant women (n = 32) at 1,820 ng/ml (interquartile range, 1,300 to 2,610 ng/ml) versus 2,760 ng/ml (interquartile range, 2,020 to 5,640 ng/ml), respectively (P = 0.006). The lumefantrine area under the concentration-time curve from 0 to 96 h was significantly higher in pregnant women (n = 27) at 155,832 ng · h/ml (interquartile range, 102,400 to 214,011 ng · h/ml) than nonpregnant women at 90,594 ng · h/ml (interquartile range, 58,869 to 149,775 ng · h/ml) (P = 0.03). A similar trend was observed for the lumefantrine concentration at 12 h after the last dose of lumefantrine, which was 2,870 ng/ml (interquartile range, 2,180 to 4,880 ng/ml) versus 2,080 ng/ml (interquartile range, 1,190 to 2,970 ng/ml) in pregnant and nonpregnant women, respectively (P = 0.02). The lumefantrine-to-desbutyl-lumefantrine ratio also tended to be lower in pregnant women than in nonpregnant women (P = 0.076). Overall, pregnancy tempered the extent of efavirenz-lumefantrine interactions, resulting in increased lumefantrine exposure. However, any consideration of dosage adjustment for artemether-lumefantrine to enhance exposure in this population needs to be based on data from a prospective study with safety and efficacy endpoints.

Item Type: Article
Uncontrolled Keywords: antimalarial agents, antiretroviral agents, drug interactions, efavirenz, human immunodeficiency virus, lumefantrine, pharmacokinetics
Depositing User: Symplectic Admin
Date Deposited: 18 Oct 2018 10:11
Last Modified: 27 Jan 2023 02:52
DOI: 10.1128/AAC.01252-18
Open Access URL: https://aac.asm.org/content/aac/62/10/e01252-18.fu...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3027689